A Round-Up of the Important Business News: Complementary Research on Cellectar, Akers, InfuSystem, 22nd Century and Cardiome

NEW YORK, May 18, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Cellectar Biosciences, Inc. (NASDAQ: CLRB), Akers Biosciences Inc. (NASDAQ: AKER), InfuSystem Holdings, Inc. (NYSE MKT: INFU), 22nd Century Group, Inc. (NYSE MKT: XXII), and Cardiome Pharma Corp. (NASDAQ: CRME). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.    

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

CLRB Research Report: ( http://get.analystsreview.com/pdf/?c=Cellectar&d=18-May-2015&s=CLRB ),

AKER Research Report: ( http://get.analystsreview.com/pdf/?c=Akers&d=18-May-2015&s=AKER ),

INFU Research Report: ( http://get.analystsreview.com/pdf/?c=InfuSystem&d=18-May-2015&s=INFU ),

XXII Research Report: ( http://get.analystsreview.com/pdf/?c=22nd%20Century&d=18-May-2015&s=XXII ),

CRME Research Report: ( http://get.analystsreview.com/pdf/?c=Cardiome&d=18-May-2015&s=CRME ).

============

--

Analyst Update: Financial Results, Clinical Trial Updates and New Offerings 

U.S. stocks mostly drifted between modest gains and losses on Friday, May 15, 2015 as investors remained cautious over weaker than expected economic data. The Dow Jones Industrial Average gained 0.11%, to finish at 18,272.56, the S&P 500 rose 0.08%, to 2,122.73, and the NASDAQ Composite ended the day at 5,048.29, down 0.05%. European stocks closed lower on Friday amid rise in the value of euro against dollar. Germany's DAX 30 lost 0.98%, France's CAC 40 fell 0.71%, and London's FTSE 100 closed 0.18% lower on Friday. Meanwhile, Asian markets painted a mixed picture on Friday. The Shanghai Composite fell as expectation of Chinese stimulus measures cooled, while Hong Kong's Hang Seng and Japan's Nikkei gained on Friday.

Cellectar Biosciences, Inc. recently announced the initiation of patient dosing in a proof-of-concept trial of I-131-CLR1404 in patients with relapsed or refractory multiple myeloma, an indication for which I-131-CLR1404 previously received orphan drug designation from the U.S. Food and Drug Administration.

On May 12, 2015, Akers Biosciences, Inc. announced that it had introduced two new breath tests - BreathScan® OxiChekTM (OxiChek™) and BreathScan® KetoChekTM (KetoChek™), to the U.S. market from the Company's Akers Wellness division.

InfuSystem Holdings, Inc. announced its financial results for the first quarter of 2015. The Company reported a 12% increase in net collected rental revenues on a Y-o-Y basis. During the quarter, the Company saw its gross margins improving by 224 basis points to 72.3%. The Company also managed to arrange a new credit facility of $45 million at a substantially lower rate of approximately 3%.

On May 11, 2015, 22nd Century Group, Inc. announced its financial results and business updates for the first quarter of 2015. The Company reported net revenues of $0.62 million for Q1 FY15 versus $0.48 million for the three months ended March 31, 2014. During the quarter, the Company's loss narrowed down to $4.1 million or $0.06 loss per share compared to net loss of $5.3 million or $0.09 loss per share in the same period prior year.

On May 13, 2015, Cardiome Pharma Corp. reported its financial results for the first quarter 2015 and also provided business updates. The Company's revenue for Q1 2015 was $5.5 million, lower from $7.6 million for Q1 2014, impacted by foreign exchange, timing of distributor sales, and due to a decrease in AGGRASTAT® sales due to generic competition. 

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.